The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Pulmonary Arterial Hypertension Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.
The global Pulmonary Arterial Hypertension Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Arterial Hypertension Treatment in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Pulmonary Arterial Hypertension Treatment market. Vasodilators, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Phosphodiesterase 5 (PDE 5) Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pulmonary Arterial Hypertension Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pulmonary Arterial Hypertension Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pulmonary Arterial Hypertension Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pulmonary Arterial Hypertension Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pulmonary Arterial Hypertension Treatment covered in this report include GSK, Eli Lilly and Company, Pfizer Inc, Actelion Inc, United Therapeutic Corporation, SteadyMed Ltd, Gilead Sciences, Inc, Teva Pharmaceuticals Inc and Bayer AG, etc.
The global Pulmonary Arterial Hypertension Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
Eli Lilly and Company
Pfizer Inc
Actelion Inc
United Therapeutic Corporation
SteadyMed Ltd
Gilead Sciences, Inc
Teva Pharmaceuticals Inc
Bayer AG
Global Pulmonary Arterial Hypertension Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pulmonary Arterial Hypertension Treatment market, Segment by Type:
Vasodilators
Phosphodiesterase 5 (PDE 5) Inhibitors
Endothelin Receptor Antagonists (ERA)
Soluble Guanylate Cyclase (SGC) Stimulator
Global Pulmonary Arterial Hypertension Treatment market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pulmonary Arterial Hypertension Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Pulmonary arterial hypertension- commonly known as PAH- is characterized by increased pressure in the pulmonary arteries due to structural changes in blood vessel walls, aggregation of platelets and alteration of smooth muscle cell function- eventually elevating pressure in the pulmonary arteries responsible for pumping blood to the lungs. This eventually leads to right heart failure and, ultimately, death.
The global Pulmonary Arterial Hypertension Treatment market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Pulmonary Arterial Hypertension Treatment in various end use industries. The expanding demands from the Hospital Pharmacies, Retail Pharmacies and Online Pharmacies,, are propelling Pulmonary Arterial Hypertension Treatment market. Vasodilators, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Phosphodiesterase 5 (PDE 5) Inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Pulmonary Arterial Hypertension Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Pulmonary Arterial Hypertension Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Pulmonary Arterial Hypertension Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Pulmonary Arterial Hypertension Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Pulmonary Arterial Hypertension Treatment covered in this report include GSK, Eli Lilly and Company, Pfizer Inc, Actelion Inc, United Therapeutic Corporation, SteadyMed Ltd, Gilead Sciences, Inc, Teva Pharmaceuticals Inc and Bayer AG, etc.
The global Pulmonary Arterial Hypertension Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GSK
Eli Lilly and Company
Pfizer Inc
Actelion Inc
United Therapeutic Corporation
SteadyMed Ltd
Gilead Sciences, Inc
Teva Pharmaceuticals Inc
Bayer AG
Global Pulmonary Arterial Hypertension Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Pulmonary Arterial Hypertension Treatment market, Segment by Type:
Vasodilators
Phosphodiesterase 5 (PDE 5) Inhibitors
Endothelin Receptor Antagonists (ERA)
Soluble Guanylate Cyclase (SGC) Stimulator
Global Pulmonary Arterial Hypertension Treatment market, by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Pulmonary Arterial Hypertension Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Pulmonary Arterial Hypertension Treatment
1.1 Pulmonary Arterial Hypertension Treatment Market Overview
1.1.1 Pulmonary Arterial Hypertension Treatment Product Scope
1.1.2 Pulmonary Arterial Hypertension Treatment Market Status and Outlook
1.2 Global Pulmonary Arterial Hypertension Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Pulmonary Arterial Hypertension Treatment Market Size by Region (2018-2029)
1.4 Global Pulmonary Arterial Hypertension Treatment Historic Market Size by Region (2018-2023)
1.5 Global Pulmonary Arterial Hypertension Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Pulmonary Arterial Hypertension Treatment Market Size (2018-2029)
1.6.1 North America Pulmonary Arterial Hypertension Treatment Market Size (2018-2029)
1.6.2 Europe Pulmonary Arterial Hypertension Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size (2018-2029)
1.6.4 Latin America Pulmonary Arterial Hypertension Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size (2018-2029)
2 Pulmonary Arterial Hypertension Treatment Market by Type
2.1 Introduction
2.1.1 Vasodilators
2.1.2 Phosphodiesterase 5 (PDE 5) Inhibitors
2.1.3 Endothelin Receptor Antagonists (ERA)
2.1.4 Soluble Guanylate Cyclase (SGC) Stimulator
2.2 Global Pulmonary Arterial Hypertension Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Pulmonary Arterial Hypertension Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Pulmonary Arterial Hypertension Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Pulmonary Arterial Hypertension Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Pulmonary Arterial Hypertension Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Breakdown by Type (2018-2029)
3 Pulmonary Arterial Hypertension Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospital Pharmacies
3.1.2 Retail Pharmacies
3.1.3 Online Pharmacies
3.2 Global Pulmonary Arterial Hypertension Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Pulmonary Arterial Hypertension Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Pulmonary Arterial Hypertension Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Pulmonary Arterial Hypertension Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Pulmonary Arterial Hypertension Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Pulmonary Arterial Hypertension Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Pulmonary Arterial Hypertension Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Pulmonary Arterial Hypertension Treatment Revenue Breakdown by Application (2018-2029)
4 Pulmonary Arterial Hypertension Treatment Competition Analysis by Players
4.1 Global Pulmonary Arterial Hypertension Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Pulmonary Arterial Hypertension Treatment as of 2022)
4.3 Date of Key Players Enter into Pulmonary Arterial Hypertension Treatment Market
4.4 Global Top Players Pulmonary Arterial Hypertension Treatment Headquarters and Area Served
4.5 Key Players Pulmonary Arterial Hypertension Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Pulmonary Arterial Hypertension Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GSK
5.1.1 GSK Profile
5.1.2 GSK Main Business
5.1.3 GSK Pulmonary Arterial Hypertension Treatment Products, Services and Solutions
5.1.4 GSK Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 GSK Recent Developments
5.2 Eli Lilly and Company
5.2.1 Eli Lilly and Company Profile
5.2.2 Eli Lilly and Company Main Business
5.2.3 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Products, Services and Solutions
5.2.4 Eli Lilly and Company Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Eli Lilly and Company Recent Developments
5.3 Pfizer Inc
5.3.1 Pfizer Inc Profile
5.3.2 Pfizer Inc Main Business
5.3.3 Pfizer Inc Pulmonary Arterial Hypertension Treatment Products, Services and Solutions
5.3.4 Pfizer Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Actelion Inc Recent Developments
5.4 Actelion Inc
5.4.1 Actelion Inc Profile
5.4.2 Actelion Inc Main Business
5.4.3 Actelion Inc Pulmonary Arterial Hypertension Treatment Products, Services and Solutions
5.4.4 Actelion Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Actelion Inc Recent Developments
5.5 United Therapeutic Corporation
5.5.1 United Therapeutic Corporation Profile
5.5.2 United Therapeutic Corporation Main Business
5.5.3 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Products, Services and Solutions
5.5.4 United Therapeutic Corporation Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 United Therapeutic Corporation Recent Developments
5.6 SteadyMed Ltd
5.6.1 SteadyMed Ltd Profile
5.6.2 SteadyMed Ltd Main Business
5.6.3 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Products, Services and Solutions
5.6.4 SteadyMed Ltd Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 SteadyMed Ltd Recent Developments
5.7 Gilead Sciences, Inc
5.7.1 Gilead Sciences, Inc Profile
5.7.2 Gilead Sciences, Inc Main Business
5.7.3 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Products, Services and Solutions
5.7.4 Gilead Sciences, Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) & (2018-2023)
5.7.5 Gilead Sciences, Inc Recent Developments
5.8 Teva Pharmaceuticals Inc
5.8.1 Teva Pharmaceuticals Inc Profile
5.8.2 Teva Pharmaceuticals Inc Main Business
5.8.3 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Products, Services and Solutions
5.8.4 Teva Pharmaceuticals Inc Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) & (2018-2023)
5.8.5 Teva Pharmaceuticals Inc Recent Developments
5.9 Bayer AG
5.9.1 Bayer AG Profile
5.9.2 Bayer AG Main Business
5.9.3 Bayer AG Pulmonary Arterial Hypertension Treatment Products, Services and Solutions
5.9.4 Bayer AG Pulmonary Arterial Hypertension Treatment Revenue (US$ Million) & (2018-2023)
5.9.5 Bayer AG Recent Developments
6 North America
6.1 North America Pulmonary Arterial Hypertension Treatment Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Pulmonary Arterial Hypertension Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Pulmonary Arterial Hypertension Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Pulmonary Arterial Hypertension Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Pulmonary Arterial Hypertension Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Pulmonary Arterial Hypertension Treatment Market Dynamics
11.1 Pulmonary Arterial Hypertension Treatment Industry Trends
11.2 Pulmonary Arterial Hypertension Treatment Market Drivers
11.3 Pulmonary Arterial Hypertension Treatment Market Challenges
11.4 Pulmonary Arterial Hypertension Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
